Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S was incorporated in 1997 and is based in Søborg, Denmark. Show more

Location: Sydmarken 11, Søborg, 2860, Denmark | Website: https://www.zealandpharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

5.615B

52 Wk Range

$49.98 - $126.00

Previous Close

$79.75

Open

$78.86

Volume

119

Day Range

$78.86 - $78.86

Enterprise Value

3.042B

Cash

16.58B

Avg Qtr Burn

N/A

Insider Ownership

0.32%

Institutional Own.

61.43%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Glepaglutide Details
Short bowel syndrome

NDA

Resubmission

Dasiglucagon Details
Congenital Hyperinsulinism

NDA

Resubmission

Survodutide/ BI456906 (GLP-1R/GCGR) Details
Non-alcoholic steatohepatitis , metabolic dysfunction-associated steatohepatitis

Phase 3

Data readout

Phase 3

Data readout

Dasiglucagon Details
Type 1 diabetes

Phase 3

Update

Phase 2b

Data readout

Petrelintide (ZP8396) Details
Overweight or obesity and type 2 diabetes

Phase 2b

Data readout

Phase 1b

Update

Phase 1

Initiation

Dasiglucagon Details
Type 1 diabetes

Failed

Discontinued